Last reviewed · How we verify
NCT04951245: UltraCars
Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy
Phase 3 trial testing UC group: ultrasound-assisted CNSs guided in Breast Cancer in 330 participants. Completed in 1 June 2021.
30 April 2021
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 330 |
| Start date | 1 December 2019 |
| Primary completion | 30 April 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- UC group: ultrasound-assisted CNSs guided
- GC group: CNSs plus ICG dual-tracer-guided
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Guangdong Provincial People's Hospital
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators suggested ultrasound-assisted Carbon nanoparticle suspensions (CNSs) mapping had great clinical value in clinical application and might serve as a useful alternative to the dual-tracer-guided SLNB. The investigators designed this prospective, randomized controlled phase 3 trial, to compare the feasibility and diagnostic performance of ultrasound-assisted carbon nanoparticle suspensions mapping versus dual-tracer-guided sentinel lymph node biopsy in patients with early breast cancer.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
TME-Related Biomimetic Strategies Against Cancer.
Peng C, Xu Y, Wu J, Wu D, et al · · 2024 · cited 57× · PMID 38192633 · DOI 10.2147/ijn.s441135 -
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.
Oehler JB, Rajapaksha W, Albrecht H. · · 2024 · cited 16× · PMID 39063977 · DOI 10.3390/jpm14070723 -
Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial.
Zhang L, Cheng M, Lin Y, Zhang J, et al · · 2022 · cited 16× · PMID 36074703 · DOI 10.1093/bjs/znac311 -
Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.
Wu L, He C, Zhao T, Li T, et al · · 2024 · cited 6× · PMID 38918821 · DOI 10.1186/s12951-024-02644-9 -
Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics.
Shi J, Fan Y, Zhang Q, Huang Y, et al · · 2025 · cited 4× · PMID 40376855 · DOI 10.1002/adma.202501623 -
Advancements in nanotechnology for diagnostics: a literature review, part II: advanced techniques in nuclear and optical imaging.
Butt A, Bach H. · · 2025 · cited 2× · PMID 39670826 · DOI 10.1080/17435889.2024.2439778 -
Recent advances in application of hydrogel-based nanomaterials in breast cancer: from drug delivery, immunotherapy mechanisms to clinical applications.
Xu Y, Pan D, Yang Q, Huang C, et al · · 2026 · PMID 41857574 · DOI 10.1186/s12951-026-04238-z
Verify or expand the search:
- PubMed search for NCT04951245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04951245 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 28 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing